BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 27113098)

  • 1. CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer.
    Wu YY; Hwang YT; Perng WC; Chian CF; Ho CL; Lee SC; Chang H; Terng HJ; Chao TY
    J Formos Med Assoc; 2017 Feb; 116(2):114-122. PubMed ID: 27113098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panels of tumor-derived RNA markers in peripheral blood of patients with non-small cell lung cancer: their dependence on age, gender and clinical stages.
    Chian CF; Hwang YT; Terng HJ; Lee SC; Chao TY; Chang H; Ho CL; Wu YY; Perng WC
    Oncotarget; 2016 Aug; 7(31):50582-50595. PubMed ID: 27418131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
    Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.
    Skrzypski M; Dziadziuszko R; Jassem E; Szymanowska-Narloch A; Gulida G; Rzepko R; Biernat W; Taron M; Jelitto-Górska M; Marjański T; Rzyman W; Rosell R; Jassem J
    Clin Lung Cancer; 2013 Nov; 14(6):666-673.e2. PubMed ID: 23870818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of microRNA-10b expression in peripheral blood mononuclear cells in evaluating short- and long-term efficacy of chemotherapy for patients with advanced non-small-cell lung cancer.
    Yang YL; Wang W; Xu LP
    Neoplasma; 2018; 65(4):610-619. PubMed ID: 30064233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered miR-143 and miR-150 expressions in peripheral blood mononuclear cells for diagnosis of non-small cell lung cancer.
    Zeng XL; Zhang SY; Zheng JF; Yuan H; Wang Y
    Chin Med J (Engl); 2013 Dec; 126(23):4510-6. PubMed ID: 24286416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential signature of eight long non-coding RNAs predicts survival in patients with non-small cell lung cancer.
    Zhou M; Guo M; He D; Wang X; Cui Y; Yang H; Hao D; Sun J
    J Transl Med; 2015 Jul; 13():231. PubMed ID: 26183581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
    Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
    Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral immune cell gene expression predicts survival of patients with non-small cell lung cancer.
    Kossenkov AV; Dawany N; Evans TL; Kucharczuk JC; Albelda SM; Showe LC; Showe MK; Vachani A
    PLoS One; 2012; 7(3):e34392. PubMed ID: 22479623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
    Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
    Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
    Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
    Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
    Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
    Burczynski ME; Twine NC; Dukart G; Marshall B; Hidalgo M; Stadler WM; Logan T; Dutcher J; Hudes G; Trepicchio WL; Strahs A; Immermann F; Slonim DK; Dorner AJ
    Clin Cancer Res; 2005 Feb; 11(3):1181-9. PubMed ID: 15709187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival.
    Bai Y; Wang YL; Yao WJ; Guo L; Xi HF; Li SY; Zhao BS
    Int J Clin Exp Pathol; 2015; 8(1):824-9. PubMed ID: 25755781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
    Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
    PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer.
    Sakashita H; Inoue H; Akamine S; Ishida T; Inase N; Shirao K; Mori M; Mimori K
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S590-8. PubMed ID: 23812770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.